TR201717703A2 - APIXABAN FORMULATIONS - Google Patents
APIXABAN FORMULATIONS Download PDFInfo
- Publication number
- TR201717703A2 TR201717703A2 TR2017/17703A TR201717703A TR201717703A2 TR 201717703 A2 TR201717703 A2 TR 201717703A2 TR 2017/17703 A TR2017/17703 A TR 2017/17703A TR 201717703 A TR201717703 A TR 201717703A TR 201717703 A2 TR201717703 A2 TR 201717703A2
- Authority
- TR
- Turkey
- Prior art keywords
- apixaban
- formulations
- apixaban formulations
- prevention
- pharmaceutically acceptable
- Prior art date
Links
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003886 apixaban Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Mevcut buluş apiksaban veya farmasötik olarak kabul edilebilir bir tuzunu içeren oral farmasötik formülasyonlar için üretim yöntemine ve bu yöntemle üretilen formülasyonların tromboembolik hastalıkların önlenmesinde ve/veya tedavi edilmesinde kullanılmasına ilişkindir.The present invention relates to a production method for oral pharmaceutical formulations containing apixaban or a pharmaceutically acceptable salt thereof, and the use of formulations produced by this method in the prevention and / or treatment of thromboembolic diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/17703A TR201717703A2 (en) | 2017-11-10 | 2017-11-10 | APIXABAN FORMULATIONS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/17703A TR201717703A2 (en) | 2017-11-10 | 2017-11-10 | APIXABAN FORMULATIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201717703A2 true TR201717703A2 (en) | 2019-05-21 |
Family
ID=67954923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2017/17703A TR201717703A2 (en) | 2017-11-10 | 2017-11-10 | APIXABAN FORMULATIONS |
Country Status (1)
| Country | Link |
|---|---|
| TR (1) | TR201717703A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022010437A1 (en) * | 2020-07-07 | 2022-01-13 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A tablet comprising apixaban |
-
2017
- 2017-11-10 TR TR2017/17703A patent/TR201717703A2/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022010437A1 (en) * | 2020-07-07 | 2022-01-13 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A tablet comprising apixaban |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202202711B (en) | Sustained-release dosage forms of ruxolitinib | |
| PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
| EA201591751A1 (en) | TRIPEPTIDE EPOKEKETONE PROTEASE INHIBITORS | |
| MX2018003569A (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses. | |
| MA39765A (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
| EA201500112A1 (en) | 3-SUBSTITUTED DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAENA, METHODS OF THEIR PRODUCTION, PHARMACEUTICAL MEANS, WHICH CONTAIN THEM, AND THEIR USE FOR RECEPTION OF MEDICINES | |
| MX2021002321A (en) | Novel methods. | |
| MX2021010297A (en) | Human plasma kallikrein inhibitors. | |
| MX2019001634A (en) | Amide compounds, pharmaceutical compositions thereof, and methods of using the same. | |
| EA201692111A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES | |
| EA201692020A1 (en) | PROTECTIVE MEANS OF AMERICA ACID FOR APPLICATION IN THE TREATMENT OF LACTOACIDOSIS OR INDIVIDUAL BY MEDICINAL MEANS OF THE DIFFERENT ACTION DUE TO THE COMPLEX I AND OXIDATIVE DISORDERS OF OXIDATIVE CHEMICAL REFERENCES AGREES | |
| TR201819805T4 (en) | FLAVAGLIN DERIVATIVES. | |
| TR201819662T4 (en) | Orally dispersible film composition containing enalapril for the treatment of childhood hypertension. | |
| PH12016502568A1 (en) | Novel heterocyclic compound | |
| EA202090913A1 (en) | COMPOSITION OF MODIFIED RELEASE TABLETS CONTAINING MIRABEGRON | |
| EA201892842A1 (en) | PHARMACEUTICAL COMPOSITIONS, INCLUDING SAFINAMID | |
| EA201691796A1 (en) | N-SUBSTITUTED ASYMMETRIC UREA AND THEIR APPLICATION IN MEDICINE | |
| CY1123394T1 (en) | PHARMACEUTICAL COMPOSITION | |
| TR201717703A2 (en) | APIXABAN FORMULATIONS | |
| EA201991286A1 (en) | A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| TR201713326A2 (en) | Production Method for Formulations Containing Rivaroxaban | |
| TR201713325A2 (en) | PRODUCTION METHOD FOR FORMULATIONS CONTAINING RIVAROXABAN | |
| MX2016016061A (en) | 2,2,2-trifluoroethyl-thiadiazines. | |
| TR201719926A2 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING PHARMACEUTICALLY ACCEPTABLE LITHIUM SALTS AND VITAMIN C |